Fig. 5
From: Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
Sugar-based AM NPs (M12PEG) showed atherosclerotic lesion-specific localization. a Schematic diagram demonstrating the favorable effect of sugar-based AM NPs on atherosclerotic plaque removal. b Fluorescence images revealing specific lesion targeting by M12PEG (red) at 24 h postinjection. c Ex vivo aortic arch fluorescence images demonstrate the highest levels of NP accumulation up to 60 days. d NP accumulation (red) within atherosclerotic plaques. Intravenous administration of AM NPs in ApoE−/− mice demonstrated in vivo efficacy by mitigating atherosclerotic endpoints. e Reduction in lipid burden and plaque development confirmed using Oil Red O staining. f M12PEG efficacy at regions of plaque formation in aorta, including the prevention of lipid and cholesterol formation (Oil Red O images), neointimal hyperplasia (smooth muscle cell, α-actin images), and inflammation (COX-2 images), as indicated by the arrows. g M12PEG resulted in a decrease in aorta occlusion, while the control NP formulation (PS14PEG NPs) and ApoE−/− mice showed no improvement. Reproduced from ref. 154
